Alpha Tau Medical Analyst Ratings
Alpha Tau Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 603.36% | Cantor Fitzgerald | → $23 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 175.23% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/24/2023 | 175.23% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/18/2023 | 175.23% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/15/2023 | 175.23% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 04/24/2023 | 175.23% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 11/23/2022 | 266.97% | Piper Sandler | $19 → $12 | Maintains | Overweight |
| 04/14/2022 | 511.62% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 04/08/2022 | 481.04% | Piper Sandler | → $19 | Initiates Coverage On | → Overweight |
| 04/04/2022 | 542.2% | Citigroup | → $21 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月29日 | 603.36% | 康托·菲茨杰拉德 | →$23 | 重申 | 超重→超重 |
| 2023年08月18日 | 175.23% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年05月24日 | 175.23% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年05月18日 | 175.23% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年05月15日 | 175.23% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 04/24/2023 | 175.23% | HC Wainwright公司 | →$9 | 开始承保 | →购买 |
| 2022年11月23日 | 266.97% | 派珀·桑德勒 | $19→$12 | 维护 | 超重 |
| 04/14/2022 | 511.62% | 康托·菲茨杰拉德 | →$20 | 开始承保 | →超重 |
| 04/08/2022 | 481.04% | 派珀·桑德勒 | →$19 | 开始承保 | →超重 |
| 04/04/2022 | 542.2% | 花旗集团 | →$21 | 开始承保 | →购买 |
What is the target price for Alpha Tau Medical (DRTS)?
Alpha Tau Medical(DRTS)的目标价格是多少？
The latest price target for Alpha Tau Medical (NASDAQ: DRTS) was reported by Cantor Fitzgerald on August 29, 2023. The analyst firm set a price target for $23.00 expecting DRTS to rise to within 12 months (a possible 603.36% upside). 7 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年8月29日报道了阿尔法头医疗公司(纳斯达克：DRTS)的最新目标价。这家分析公司将目标价定为2300美元，预计DRTS将在12个月内升至(可能上涨603.36%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Alpha Tau Medical (DRTS)?
Alpha Tau Medical(DRTS)的最新分析师评级是什么？
The latest analyst rating for Alpha Tau Medical (NASDAQ: DRTS) was provided by Cantor Fitzgerald, and Alpha Tau Medical reiterated their overweight rating.
阿尔法头医疗(纳斯达克股票代码：DRTS)的最新分析师评级由坎托·菲茨杰拉德提供，阿尔法头医疗重申其增持评级。
When is the next analyst rating going to be posted or updated for Alpha Tau Medical (DRTS)?
Alpha Tau Medical(DRTS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alpha Tau Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alpha Tau Medical was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与阿尔法塔医疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Alpha Tau Medical的上一次评级是在2023年8月29日提交的，因此您应该预计下一次评级将在2024年8月29日左右的某个时候提供。
Is the Analyst Rating Alpha Tau Medical (DRTS) correct?
分析师对Alpha Tau Medical(DRTS)的评级正确吗？
While ratings are subjective and will change, the latest Alpha Tau Medical (DRTS) rating was a reiterated with a price target of $0.00 to $23.00. The current price Alpha Tau Medical (DRTS) is trading at is $3.27, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的阿尔法头医疗(DRTS)评级被重申，目标价在0.00美元至23.00美元之间。Alpha Tau Medical(DRTS)目前的交易价格为3.27美元，在分析师的预测范围内。